45 patients with Non–Small-Cell Lung Cancer (NSCLC) who received the 600-mg dose, 36% had a partial response, the median progression-free survival (PFS) was 8.3 months, estimated 12-month overall survival was 59% 21 patients with metastatic pancreatic ductal adenocarcinoma 24% had a response, the median PFS was 3.0 months and the median overall survival was 10.3 months.
At 2 years, estimated event-free survival was 74.7% in the enfortumab vedotin–pembrolizumab group and 39.4% in the control group (hazard ratio) HR 0.4 estimated overall survival was 79.7% and 63.1% HR 0.50. Perioperative enfortumab vedotin plus pembrolizumab new standard of care for cisplatin ineligible patients who are candidates for surgery.
Study compared CAPOX vs radiation with capecitabine. Locoregional recurrence free survival (LRRFS) was the primary end point. 3-year LRRFS was 97.4% in the nCRT group and 96.3% in the nCT group, DFS 89.2% v 87.9% 3-year overall survival (OS) 95.0% v 94.1% were similar. The nCT group showed a lower incidence of grade 2 to 4 long-term AEs 16.0% v 26.3% and proctitis 33.6% v 41.7% compared with nCRT group, nCT offers comparable DFS and OS while mitigating the burden of toxicity as compared to nCRT.
Gedatolisib potently targets all four class I PI3K isoforms and mTORC1 and mTORC2 to comprehensively block the PI3K/AKT/mTOR pathway. PFS was 9.3 m in the gedatolisib-triplet group vs 2.0 m in the fulvestrant group (hazard ratio) HR 0.24, and 7.4 m in the gedatolisib-doublet group HR 0.33 v fulvestrant.
Combination improved progression-free survival (PFS) 6.2 months vs 2.8 months, hazard ratio (HR) 0.64 but not overall survival (OS) (15 months for combination vs 17.9 months for pembro), no safety concerns. Overall, although the combination demonstrated a clinically meaningful PFS advantage, the absence of an OS benefit limits its impact on standard first-line treatment, where survival remains the key endpoint.
This is an impressive advance in allo transplant, Orca-T cutting moderate–severe cGVHD dramatically (≈13% vs 44%) and nearly doubling cGVHD-free survival at 1 year (78% vs 38%) while also lowering NRM and serious infections is hard to ignore. Overall survival (OS) isn’t statistically different yet, but the combination of better disease control, less toxicity, and preserved immune reconstitution makes this feel like a meaningful step toward safer, more “engineered” transplants rather than just better immunosuppression.
This is a nice reminder that immune checkpoint inhibitors (ICI)-associated immune thrombocytopenia (ITP) is uncommon but definitely not benign~1 in 400 incidence with a meaningful subset recurring on rechallenge of 30%, and while most patients recover, severity clearly tracks with worse outcomes including higher mortality. It reinforces that even “rare” hematologic irAEs can carry real clinical weight, so early recognition and thoughtful decisions around rechallenge are key.
This is starting to look like a real frontline disruptor in chronic myeloid leukemia (CML), asciminib showing a pretty striking ~22% absolute improvement in MMR at 96 weeks vs investigator-selected TKIs (and nearly 30% over imatinib) with a cleaner tolerability profile makes a strong case for moving beyond ATP-competitive tyrosine kinase inhibitors (TKIs) upfront. The efficacy signal is consistent across depths of response and durability looks excellent, with fewer discontinuations, overall survival (OS) will take time, but this feels very competitive as a new standard option.
In this Korean retrospective review of >6MM patients, heavy ethanol consumption in patients between 20-39 years of age was associated with associated with about a 20% increased risk of pancreatic cancer. This should be taken with a grain of salt (not on your margarita) but does suggest a dose dependent effect of ethanol use and pancreatic cancer risk.
Interesting study that quantifies the risk of Venous Thromboembolism (VTE) in patients undergoing neo(adjuvant) treatment. Risk was about 9% overall, underscoring the need to be aware and potentially provide prophylaxis where appropriate.